
Magali, a village nurse administers the Covid-19 vaccine to senior citizen at the Plan health center, on March 3, 2021 in Plan, Spain. The community of Aragon, Spain, is beginning to vaccinate people who cannot travel to vaccination centers with the Pfizer-BioNtech Covid-19 vaccine at their homes in rural mountain villages.
Alvaro Calvo—Getty Images
After playing a critical role in curbing COVID-19 disease with its vaccine, Pfizer and CEO Albert Bourla late last year introduced an oral antiviral therapy to treat those at highest risk of severe illness. The two-drug combination is the first pill-based coronavirus treatment in the U.S., and can reduce the risk of hospitalization or death by up to 89%. Demand for Paxlovid, which has received emergency-use authorization from the U.S. Food and Drug Administration, will likely increase under the White House’s plan to broaden access to such therapies with its Test to Treat initiative.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief
More Must-Read Stories From TIME
- Meet TIME’s Newest Class of Next Generation Leaders
- After Visiting Both Ends of the Earth, I Realized How Much Trouble We’re In
- Google Is Making It Easier to Remove Personal Info From Search
- Oil Companies Posted Huge Profits. Here’s Where The Cash Will Go (Hint: Not Climate)
- Column: We Asked Hundreds of Americans About Abortion. Their Feelings Were Complicated
- A Short History of the Rise, Fall, and Rise Again of the Marcos Family
- Long-Lasting Birth Control Is Already Hard to Get. Advocates Worry It May Only Get Worse
- Who Should Be on the 2022 TIME100? Vote Now